Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesImunon Inc

Imunon Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.7201 USD -0.05 ( 6.48%)
Last update at 2026-11-11T21:00:00Z
VOLUME
126478
Market Cap
7.86M

Momentum Score

…

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.68
Low
0.80
High
52 Week Price Range
1.39
Low
5.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Imunon Inc (IMNN) is limited; company filings, product descriptions and investor materials are sparse and do not clearly document its core business or pipeline. Given this lack of disclosure, investors cannot reliably identify major long-term growth drivers, although small-cap biotechnology firms generally may benefit from successful clinical data, partnerships and regulatory approvals; stakeholders should monitor SEC filings and corporate announcements.
Primary investment risks include significant informational opacity, likely early-stage or undeveloped operations, high financing and execution risk, and exposure to regulatory and clinical binary outcomes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.77
Dividend Yield
-
Revenue TTM
0.12M
Revenue Per Share
0.01
Gross Profit TTM
-0.41M
Debt / Equity
0.14
ROE
-429.72%
Net Debt
-7.77M
ROCE
-189.13%
Diluted EPS TTM
-2.92

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.50M -18.62M -20.80M -37.47M -22.15M
Net income -14.49M -18.62M -19.51M -35.90M -20.77M
Selling general administrative 6.87M 7.49M 9.74M 13.69M 10.89M
Selling and marketing expenses - - 9733.72M - -
Gross profit - -0.72M -0.72M 0.50M 0.50M
Reconciled depreciation 0.70M 0.72M 0.80M 0.73M 0.70M
Ebit -14.50M -18.62M -20.60M -24.92M -21.01M
Ebitda -13.80M -17.90M -19.88M -19.53M -19.39M
Depreciation and amortization 0.70M 0.72M 0.72M 5.40M 1.62M
Operating income -14.65M -19.13M -21.03M -24.92M -21.01M
Other operating expenses 14.65M 19.13M 21.03M 25.42M 21.51M
Interest expense - 0.00M 0.20M 4.57M 0.56M
Tax provision - 0.00M -1.28M -1.57M -1.38M
Interest income - 0.45M 1.20M 0.50M 0.02M
Net interest income - 0.45M 0.85M -4.57M -0.55M
Income tax expense - - -1.28M -1.57M -1.38M
Total revenue 0.00M 0.00M 0.12M 0.50M 0.50M
Total operating expenses 14.65M 19.13M 21.03M 25.42M 21.51M
Cost of revenue - 0.72M 0.72M - -
Total other income expense net 0.16M 0.51M 0.24M -12.54M -1.15M
Net income from continuing ops -14.50M -18.62M -27.86M -35.90M -20.77M
Net income applicable to common shares - - - -35.90M -20.77M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 12.29M 9.72M 21.92M 43.98M 74.05M
Intangible assets - - - - 13.37M
Other current assets 1.94M 2.14M 2.55M 2.78M 0.00M
Total liab 5.23M 5.47M 8.53M 14.65M 18.25M
Total stockholder equity 7.06M 4.24M 13.39M 29.33M 55.80M
Other current liab 2.82M 3.03M 3.39M 4.79M 3.17M
Common stock 0.03M 0.15M 0.09M 0.07M 0.06M
Capital stock 0.03M 0.15M 0.09M 0.07M 0.06M
Retained earnings -421.30M -406.80M -388.18M -368.67M -332.77M
Other liab - - - - 5.40M
Good will - - - - 0.00M
Other assets - 0.00M 0.00M 6.12M 7.57M
Cash 8.78M 5.87M 5.84M 11.49M 19.59M
Total current liabilities 4.62M 4.79M 7.39M 10.04M 6.77M
Current deferred revenue - - - -4.79M 0.50M
Net debt -7.77M -4.73M -4.21M -5.23M -12.95M
Short term debt 0.41M 0.45M 0.49M 1.66M 0.55M
Short long term debt - - - 1.43M -
Short long term debt total 1.01M 1.14M 1.62M 6.27M 6.63M
Other stockholder equity 428.33M 410.90M 401.42M 397.89M 388.52M
Property plant equipment - - - 0.70M 1.17M
Total current assets 10.72M 8.01M 18.24M 37.16M 51.95M
Net tangible assets - - - 29.33M 42.43M
Short term investments - 0.00M 9.86M 21.38M 29.91M
Net receivables - - - 0.13M 0.11M
Long term debt - - - 4.61M 5.85M
Inventory - - - 1.37M 2.34M
Accounts payable 1.39M 1.30M 3.52M 8.38M 2.55M
Accumulated other comprehensive income - - 0.06M 0.03M -0.01M
Non currrent assets other 0.05M 0.05M 0.05M 4.50M 6.00M
Non current assets total 1.56M 1.71M 3.68M 6.82M 22.10M
Capital lease obligations 1.01M 1.14M 1.62M 0.23M 0.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 9.83M 3.46M 8.32M -29.81M
Change to liabilities - - - 0.54M -0.20M
Total cashflows from investing activities -0.28M 9.83M 11.01M 8.32M -30.12M
Net borrowings - 0.00M -6.42M - 0.57M
Total cash from financing activities 17.09M 9.06M -3.64M 6.72M 54.77M
Change to operating activities - - - 0.67M -0.77M
Net income -14.50M -18.62M -19.51M -35.90M -20.77M
Change in cash 2.91M 0.03M -11.65M -8.09M 8.42M
Begin period cash flow 5.87M 5.84M 17.49M 25.59M 17.16M
End period cash flow 8.78M 5.87M 5.84M 17.49M 25.59M
Total cash from operating activities -13.90M -18.85M -19.02M -23.13M -16.22M
Issuance of capital stock 13.63M 9.06M 3.20M 35.22M 52.69M
Depreciation 0.70M 0.72M 0.72M 0.73M 0.70M
Other cashflows from investing activities - 9905.53M - - -
Dividends paid 0.01M 0.00M - - -
Change to account receivables - - 0.07M - -
Sale purchase of stock - - 0.00M -28.50M -
Other cashflows from financing activities 17068.40M 9051.38M -6.42M 28.50M 7.27M
Change to netincome - - - 10.64M 4.58M
Capital expenditures 0.28M 0.03M 0.45M 0.27M 0.31M
Change in working capital -0.33M -2.65M -2.07M 1.21M -0.97M
Stock based compensation 0.13M 0.48M 0.76M 2.67M 3.76M
Other non cash items 0.10M -0.06M 0.79M 8.15M 0.59M
Free cash flow -14.18M -18.88M -19.47M -23.40M -16.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMNN
Imunon Inc		 -0.05
6.48%		 0.72 - 16.78 17.94 1.94 4.00 0.91
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Imunon Inc

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

997 Lenox Drive, Lawrenceville, NJ, United States, 08648

609 896 9100

https://imunon.com

20

Name Title Year Born
Mr. Michael H. Tardugno Exec. Chairman 1951
Mr. Jeffrey W. Church CPA, CPA CFO, Exec. VP & Corp. Sec. 1957
Dr. Khursheed Anwer M.B.A., Ph.D. Exec. VP & Chief Scientific Officer 1960
Dr. Nicholas Borys M.D. Exec. VP & Chief Medical Officer 1959
Dr. Corinne Le Goff M.B.A., Pharm.D. CEO, Pres & Director NA
Mr. Timothy J. Tumminello CPA Chief Accounting Officer & Controller 1958
Ms. Marianne M. Lambertson VP of Communications & Investor Relations NA
Mr. Michael H. Tardugno Executive Chairman 1951
Mr. Jeffrey W. Church CPA CFO, Executive VP & Corporate Secretary 1957
Dr. Khursheed Anwer M.B.A., Ph.D. Executive VP & Chief Scientific Officer 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…